Interstitial lung diseases, progressive phenotype: urgent problems of early diagnosis and early initiation of antifibrotic therapy


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Long-term study of the features of the clinical course of interstitial lung diseases (ILD) of various etiologies made it possible to identify a progressive fibrosing phenotype, which contributes to a rapid deterioration of the ventilation function of the lungs and, as a consequence, a decrease in the quality of life. Diagnosis of a progressive fibrotic process is based on a comprehensive analysis of respiratory clinical symptoms, a decrease in forced vital capacity (FVC) and fibrotic changes in the lungs by high-resolution computed tomography. Early detection of the disease and referral of a patient with ILD to a reference center followed by the appointment of antifibrotic therapy is the only currently proven way to improve the survival of patients with ILD.

Full Text

Restricted Access

About the authors

Natalia E. Kostina

Voronezh Regional Clinical Hospital No. 1

head of the Department of pulmonology

Irina A. Starodubtseva

N.N. Burdenko Voronezh State Medical University of the Ministry of Healthcare of Russia

MD, associate professor of the Department of propedeutics of internal diseases

Yulia A. Sharapova

N.N. Burdenko Voronezh State Medical University of the Ministry of Healthcare of Russia

PhD, associate professor of the Department of hospital therapy with the course of endocrinology

Andrey G. Malyavin

A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia

MD, professor, professor Department of phthisiology and pulmonology of the Faculty of general medicine

References

  1. Илькович М.М., Новикова Л.Н. Идиопатические интерстициальные пневмонии: объединительная концепция. Доктор.Ру. 2018; 4: 14-17.
  2. Williams E.M., Colasanti R., Wolffs K. et al. Classification of tidal breathing airflow profiles using statistical hierarchal cluster analysis in idiopathic pulmonary fibrosis. Med Sci (Basel). 2018; 6(3): 75. doi: 10.3390/medsci6030075.
  3. Lee P.J., Kanne J.P. Idiopathic interstitial pneumonias. In: Kanne J. (eds). Clinically oriented pulmonary imaging. Respiratory medicine. Humana Press; pp. 195-207. doi: 10.1007/978-1-61779-542-8_12.
  4. Patel A.S., Siegert R.J., Brignall K. et al. The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax. 2012; 67(9): 804-10. doi: 10.1136/thoraxjnl-2012-201581.
  5. Kolb M., Vasakova M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res. 2019; 20(1): 57. doi: 10.1186/ s12931-019-1022-1.
  6. Demedts M., Costabel U. ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Eur Respir J. 2002; 19(5): 794-96. doi: 10.1183/09031936.02.00492002.
  7. Travis W.D., Costabel U., Hansell D.M. et al. An Official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J. Respir Crit Care Med. 2013; 188(6): 733-48. doi: 10.1164/rccm.201308-1483ST.
  8. Fischer A., Antoniou K.M., Brown K.K. et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015; 46(4): 976-87. doi: 10.1183/13993003.00150-2015.
  9. Wells A.U., Brown K.K., Flaherty K.R. et al. What's in a name? That which we call IPF, by any other name would act the same. Eur Respir J. 2018; 51(5): 1800692. doi: 10.1183/13993003.00692-2018.
  10. Flaherty K.R., Brown K.K., Wells A.U. et al. Design of the PF ILD trial: A double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Resp Res. 2017; 4(1): e000212. doi: 10.1136/ bmjresp-2017-000212.
  11. Wijsenbeek M., Kreuter M., Olson A. et al. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Med Res Opin. 2019; 35(11): 2015-24. doi: 10.1080/03007995.2019.1647040.
  12. Walsh S., Devaraj A., Enghelmayer J.I. et al. Role of imaging in progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018; 27(150): 180073. doi: 10.1183/16000617.0073-2018.
  13. Bjoraker J.A., Ryu J.H., Edwin M.K. et al. Prognostic significance of histopathologic subsets inidiopathic pulmonary fibrosis. Am J. Respir Crit Care Med. 1998; 157(1): 199-203. doi: 10.1164/ajrccm.157.1.9704130.
  14. Travis W.D., Matsui K., Moss J. et al. Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J. Surg Pathol. 2000; 24(1): 19-33. doi: 10.1097/00000478-200001000-00003.
  15. Brown K.K., Martinez F.J., Walsh S.L.F. et al. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J. 2020; 55(6): 2000085. doi: 10.1183/13993003.00085-2020.
  16. Richeldi L., du Bois R.M., Raghu G. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl J. Med. 2014; 370(22): 2071-82. doi: 10.1056/NEJMoa1402584.
  17. Distler O., Highland K.B., Gahlemann M. et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N. Engl J. Med. 2019; 380(26): 2518-28. doi: 10.1056/NEJMoa1903076
  18. Flaherty K.R., Wells A.U., Cottin V. et al. Nintedanib in progressive fibrosing interstitial lung diseases. N. Engl J. Med. 2019; 381(18): 1718-27. doi: 10.1056/NEJMoa1908681.
  19. Lamas D.J., Kawut S., Bagiella E. et al. Delayed access and survival in idiopathic pulmonary fibrosis: A cohort study. Am J. Respir Crit Care Med. 2011; 184(7): 842-47. doi: 10.1164/rccm.201104-0668OC.
  20. Molina-Molina M., Aburto M., Acosta O. et al. Importance of early diagnosis and treatment in idiopathic pulmonary fibrosis. Expert Rev Respir Med. 2018; 12(7): 537-39. doi: 10.1080/17476348.2018.1472580.
  21. Cosgrove G.P., Bianchi P., Danese S., Lederer D.J. Barriers to timely diagnosis of interstitial lung disease in the real world: the INTENSITY survey. BMC Pulm Med. 2018; 18(1): 9. doi: 10.1186/s12890-017-0560-x.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies